131I/123I-Metaiodobenzylguanidine (MIBG) scintigraphy: Procedure guidelines for tumour imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 12, 2003, Pages

  Bombardieri, Emilio ^a   Aktolun, Cumali ^b   Baum, Richard P ^c   Bishof Delaloye, Angelika ^d   Buscombe, John ^e   Chatal, Jean François ^f   Maffioli, Lorenzo ^g   Moncayo, Roy ^h   Mortelmans, Luc ⁱ   Reske, Sven N ^j  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b KOCAELI UNIVERSITY   (Turkey)

^c PET Center   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g A MANZONI HOSPITAL   (Italy)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF ULM   (Germany)

more..

Author keywords

131I 123I MIBG scintigraphy; Indications; Procedure guidelines; Tumour imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

CANCER; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; IMAGE PROCESSING; NEUROENDOCRINE TUMOR; PRACTICE GUIDELINE; RADIATION DOSE; REVIEW; SCINTIGRAPHY; TECHNIQUE; ARTICLE; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EUROPE; HUMAN; MEDICAL SOCIETY; METHODOLOGY; NEOPLASM; NUCLEAR MEDICINE; PATIENT CARE; SCINTISCANNING; STANDARD;

3-IODOBENZYLGUANIDINE; EUROPE; HUMANS; IODINE RADIOISOTOPES; NEOPLASMS; NEUROENDOCRINE TUMORS; NUCLEAR MEDICINE; PATIENT CARE MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; SOCIETIES, MEDICAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0346103815     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1357-0     Document Type: Review

References (33)

1. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluoodeoxyglucose PET for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25:79-83.
2. Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 2001; 12:S51-S61.
3. Bonnin G, Lumbroso J, Tenebaum F, et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994; 35:803-810.
4. Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med 2003; 47:31-40.
5. Giammarile F, Boneu A, Edeline V, et al. Guide de réalisation de la scintigraphie à la meta-iodobenzylguanidine (MIBG) en oncologie pédiatrique. Med Nucl 2000; 24:35-41.
6. Gordon I, Peters AM, Gutman A, et al. Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990; 31:129-134.
7. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1987; 18:1-4.
8. ICRP Publication 62. Radiological protection in biomedical research. Ann ICRP 1991; 22:3.
9. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1998; 28:3.
10. Khafagi FA, Shapiro B, Fig LM, et al. Labetalol reduces iodine-131-MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989; 30:481-489.
11. 123I-MIBG scintigraphy and bone scan. Eur J Nucl Med 1995; 22:322-329.
12. Leung A, Shapiro B, Hattner R, et al. The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38:1352-1357.
13. Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-I123-iodobenzylguanidine (I-123 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24:672-682.
14. Olivier P, Colarinha P, Fettich J, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30:B45-B50.
15. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21:13-18.
16. Piepsz A, Hahn K, Roca I, et al. A radiopharmaceuticals schedule for imaging in paediatrics. Paediatrics Task Group European Association Nuclear Medicine. Eur J Nucl Med 1990; 17:127-129.
17. Rubello D, Bui C, Casara D, et al. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002; 147:13-28.
18. Rufini V, Giordano A, Di Giuda D, et al. 123MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 4:25-28.
19. Rufini V, Fisher GA, Shulkin BL, et al. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996; 37:1464-1468.
20. 123I-mIBG scintigraphy in neuroblastomas provides prognostic information. Med Pediatr Oncol 2000; 35:688-691.
21. 123I-MIBG. Med Pediatric Oncol 1987; 15:170-177.
22. Shulkin B, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39:679-688.
23. Shulkin B, Sisson JC, Koral KF, et al. Conjugate view gamma camera method for estimating tumor uptake of iodine-131 metaiodobenzylguanidine. J Nucl Med 1988; 29:542-548.
24. Siegel MJ, Ishwaran H, Fletcher BD, et al. Staging of neuroblastoma at imaging: report of the Radiology Diagnostic Oncology Group. Radiology 2002; 223:168-175.
25. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999; 43:217-223.
26. Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13:513-521.
27. Staalman CR, Hoefnagel CA. Imaging of neuroblastomas and metastasis. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, eds. Neuroblastoma. Amsterdam: Elsevier; 2000:303-329.
28. Stabin MG, Gelfand MJ. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42:93-112.
29. 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996; 32:1924-1932.
30. Troncone L, Rufini V. Radiolabeled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998:843-857.
31. Wafelman AR, Hoefnagel CA, Maes RAA, et al. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry. Eur J Nucl Med 1994; 21:545-559.
32. Williams ED, Siebenmann RE, Sobin LH. Histological typing of endocrine tumors. Geneva: World Health Organization; 1980:33-49.
33. Zuetenhorst JM, Hoefnagel CA, Boot H, et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002; 23:735-741.